Page 13 - Read Online

Nouso et al. Hepatoma Res 2018;4:73 I http://dx.doi.org/10.20517/2394-5079.2018.93 Page 7 of 7

Japan society of hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015; doi: 10.1111/hepr.12464.
10. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.
11. International Diabetes Federation. IDF Diabetes Atlas - 8th edition. Available from: http://www.diabetesatlas.org. [Last accessed on 4 Dec
2018].
12. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a
population-based cohort study in Japan. Eur J Cancer Prev 2009;18:26-32.
13. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive
power of transaminases. J Natl Cancer Inst 2012;104:1599-611.
14. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, et al. α-fetoprotein levels after interferon therapy and risk of
hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253-62.
15. Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based
antiviral therapy. Hepatol Res 2015;45:152-61.
16. Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, et al. Alpha-fetoprotein before and after pegylated interferon therapy for predicting
hepatocellular carcinoma development. World J Hepatol 2015;7:2220-8.
17. Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, et al. Impact of etiology of chronic liver disease on hepatocellular carcinoma
biomarkers. Cancer Biomark 2018;21:603-612.
18. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.
Hepatology 2011;53:1020-2.
19. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a
systematic review. Hepatol Int 2008;2:17-30.